Novel drug approvals set to hit a new record in 2018
Amid market volatility, biotech’s best friend comes through once again: the FDA has authorised a bumper 53 new medicines so far in 2018 and several more are expected…
After Alnylam’s solo maiden launch, here comes the tricky bit
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Neuren pays the price for sellside froth
The Australian group has found a partner for its lead asset at last, so why is the stock down?
US regulators on track for another strong year
If the US drugs regulator picks up the pace in the second half of the year, 2018 could be a bumper year for novel medicine approvals.
GW’s Dravet lock looks broken as Zogenix data scores
Battle in a rare form of epilepsy queued up following positive phase III trial.
Upcoming events – Zogenix and Mallinckrodt look to rare diseases
Zogenix and Mallinckrodt face investor scrutiny as they report critical data that will answer questions about safety and efficacy.
Canada’s medical cannabis ambition no laughing matter
Growing acceptance of medical marijuana could see cannabis companies coming after pharma sales.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.